XOMA Royalty Corp Boasts Strong Financial Growth

By Hao Liu • Wednesday, November 12 11:23 • Permanent Link

Xoma Royalty Corporation (NASDAQ: XOMA) has reported its third-quarter and year-to-date 2025 financial results, showcasing significant growth in various areas. The company's cash receipts from royalties and milestones in the first nine months of 2025 amounted to $43.9 million, with $14.3 million received in the third quarter alone.

The company's income and revenue for the three and nine months ended September 30, 2025, were $9.4 million and $38.4 million, respectively, compared to $7.2 million and $19.8 million for the corresponding periods of 2024, reflecting a substantial increase.

Furthermore, the company reported net income of $14.1 million and $25.6 million for the three and nine months ended September 30, 2025, compared to net losses of $17.2 million and $9.9 million in the corresponding periods of 2024, indicating a significant turnaround in its financial performance.

Xoma Royalty's cash and cash equivalents as of September 30, 2025, stood at $130.6 million, including $85.4 million in restricted cash. This marked a significant increase from the $106.4 million in cash and cash equivalents reported as of December 31, 2024.

The company's business achievements in the acquisition and development of assets are also noteworthy. Xoma Royalty completed acquisitions of Turnstone Biologics and Hillevax, and announced acquisitions of Lava Therapeutics and Mural Oncology, which are expected to further enhance its portfolio and potential future revenues.

Moreover, the company has been actively involved in pipeline advancements, with key updates from partners such as Zevra Therapeutics, Rezolute, Gossamer Bio, and Daré Biosciences, indicating promising developments and potential commercial opportunities.

Xoma Royalty's ability to increase its optionality within its portfolio while maintaining a healthy cash balance and limiting dilution to its shareholders has been highlighted as a key focus, demonstrating the company's commitment to delivering additional shareholder value.

Today the company's shares have moved 2.99% to a price of $34.49. For the full picture, make sure to review XOMA Royalty Corp's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.